Literature DB >> 20097594

Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis.

Béatrice Bouvard1, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand.   

Abstract

The finding of monoclonal gammopathy of undetermined significance (MGUS) is not infrequent during an evaluation for osteoporosis or a fracture. In most cases, the diagnosis is MGUS, whose prevalence increases with age. Although the impact of MGUS on bone mineral density, bone remodeling, and the fracture risk remains unclear, this asymptomatic hematological disorder may constitute a risk factor for osteoporosis. Furthermore, each year, 1% of patients with MGUS progress to multiple myeloma, a disease whose pathophysiology and association with bone loss and pathological fractures are increasingly well understood. Osteoporotic fractures, although probably common in myeloma patients, are less likely to be recognized. Here, we discuss the pathophysiology of myeloma and MGUS and their impact in terms of bone mineral density, osteoporotic fractures, and bone turnover markers. Copyright 2009 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20097594     DOI: 10.1016/j.jbspin.2009.12.002

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  7 in total

1.  Immune complexes regulate bone metabolism through FcRγ signalling.

Authors:  Takako Negishi-Koga; Hans-Jürgen Gober; Eriko Sumiya; Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Ayako Suematsu; Tomomi Suda; Kojiro Sato; Toshiyuki Takai; Hiroshi Takayanagi
Journal:  Nat Commun       Date:  2015-03-31       Impact factor: 14.919

2.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

3.  Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.

Authors:  Bernard Regidor; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Fadi Tarhini; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2020-11-25       Impact factor: 3.673

Review 4.  The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

Authors:  Paul G Richardson; Jacob P Laubach; Robert L Schlossman; Irene M Ghobrial; Constantine S Mitsiades; Jacalyn Rosenblatt; Anuj Mahindra; Noopur Raje; Nikhil Munshi; Kenneth C Anderson
Journal:  Eur J Haematol       Date:  2011-11-22       Impact factor: 2.997

Review 5.  Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.

Authors:  Patrizia Tosi
Journal:  Scientifica (Cairo)       Date:  2013-12-08

6.  Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance.

Authors:  E M Stein; A Dash; M Bucovsky; S Agarwal; J Fu; S Lentzsch; E Shane
Journal:  Osteoporos Int       Date:  2018-11-28       Impact factor: 4.507

7.  Erythropoietin receptor in B cells plays a role in bone remodeling in mice.

Authors:  Naamit Deshet-Unger; Albert Kolomansky; Nathalie Ben-Califa; Sahar Hiram-Bab; Dafna Gilboa; Tamar Liron; Maria Ibrahim; Zamzam Awida; Anton Gorodov; Howard S Oster; Moshe Mittelman; Martina Rauner; Ben Wielockx; Yankel Gabet; Drorit Neumann
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.